利马前列素结构式
|
常用名 | 利马前列素 | 英文名 | Limaprost |
|---|---|---|---|---|
| CAS号 | 74397-12-9 | 分子量 | 380.518 | |
| 密度 | 1.1±0.1 g/cm3 | 沸点 | 550.6±50.0 °C at 760 mmHg | |
| 分子式 | C22H36O5 | 熔点 | 97-100° | |
| MSDS | 中文版 美版 | 闪点 | 300.9±26.6 °C | |
| 符号 |
GHS06 |
信号词 | Danger |
利马前列素用途Limaprost(OP1206)是PGE1类似物,是血小板粘附抑制剂。 |
| 中文名 | 利马前列素 |
|---|---|
| 英文名 | (E)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S,5S)-3-hydroxy-5-methylnon-1-enyl]-5-oxocyclopentyl]hept-2-enoic acid |
| 中文别名 | 利马司特 | (2E,11Α,13E,15S,17S)-11,15-二羟基-17,20-二甲基-9-氧代前列-2,13-二烯-1-酸(2E,11Α,13E,15S,17S)-11,15-DIHYDROXY-17,20-DIMETHYL-9-OXOPROSTA-2,13-DIEN-1-OICACID |
| 英文别名 | 更多 |
| 密度 | 1.1±0.1 g/cm3 |
|---|---|
| 沸点 | 550.6±50.0 °C at 760 mmHg |
| 熔点 | 97-100° |
| 分子式 | C22H36O5 |
| 分子量 | 380.518 |
| 闪点 | 300.9±26.6 °C |
| 精确质量 | 380.256287 |
| PSA | 94.83000 |
| LogP | 3.15 |
| InChIKey | OJZYRQPMEIEQFC-UAWLTFRCSA-N |
| SMILES | CCCCC(C)CC(O)C=CC1C(O)CC(=O)C1CCCCC=CC(=O)O |
| 外观性状 | crystalline |
| 蒸汽压 | 0.0±3.4 mmHg at 25°C |
| 折射率 | 1.551 |
| 储存条件 | −20°C |
| 水溶解性 | DMF: soluble |
| 分子结构 | 1、 摩尔折射率:108.52 2、 摩尔体积(cm3/mol):340.2 3、 等张比容(90.2K):908.2 4、 表面张力(dyne/cm):50.7 5、 极化率(10-24cm3):43.02 |
| 更多 | 1.性状:白色结晶。 2.熔点(℃):97~100。 |
| 符号 |
GHS06 |
|---|---|
| 信号词 | Danger |
| 危害声明 | H300 |
| 警示性声明 | P264-P301 + P310 |
| 个人防护装备 | Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges |
| 危害码 (欧洲) | T: Toxic; |
| 风险声明 (欧洲) | 25 |
| 安全声明 (欧洲) | 36/37/39-45 |
| 危险品运输编码 | UN 2811 6.1/PG 2 |
| WGK德国 | 3 |
| RTECS号 | UK8362500 |
88mg化合物(I)和357mg4-二甲氨基吡啶溶于二氯甲烷,在冰浴冷却下加入116脚甲磺酰氯。加毕,在30℃反应2.5h,得到94%的化合物(Ⅱ)。80mg化合物(Ⅱ)和800mg锌在含乙酸的异丙醇中,在50℃反应2h,得到66%的化合物(Ⅲ)。再酸性(如三氟乙酸或甲磺酸)水解为化合物(Ⅳ),最后用猪肝酯酶水解,得到利马前列素。
|
OP-1206, a prostaglandin E1 derivative, attenuates the thermal hyperesthesia induced by constriction injury to the sciatic nerve in the rat.
Anesth. Analg. 80(3) , 515-20, (1995) Nerve ischemia induces wallerian degeneration and peripheral neuropathy, the nerve constriction injury induces thermal hyperesthesia. Nerve ischemia is one possible mechanism in the development of the... |
|
|
Inhibition of platelet aggregation by the cAMP-phosphodiesterase inhibitor, cilostamide, may not be associated with activation of cAMP-dependent protein kinase.
Cell. Signal. 4(4) , 453-63, (1992) We examined the involvement of cAMP-dependent protein kinase (A kinase)2 in the inhibition by cilostamide, a specific inhibitor of the low Km cAMP-phosphodiesterase (PDE), on 9,11-epithio-11,12-methan... |
|
|
Correlation between methotrexate-induced intestinal damage and decrease in polyamine content.
Life Sci. 72(6) , 669-76, (2002) A synthetic analog of prostaglandin E(1), OP-1206 [17S, 20-dimethyl-trans-Delta(2)-prostaglandin E(1)] protects the small intestine from the methotrexate (MTX)-induced damage. The purpose of this stud... |
| 17S,20-Dimethyl-trans-delta2-PGE1 |
| (E)-7-((1R,2R,3R)-3-Hydroxy-2-((E)-(3S,5S)-3-hydroxy-5-methyl-1-nonenyl)-5-oxocyclopentyl)-2-heptenoic acid |
| (2E)-7-{(1R,2R,3R)-3-Hydroxy-2-[(1E,3S,5S)-3-hydroxy-5-methylnon-1-en-1-yl]-5-oxocyclopentyl}hept-2-enoic acid (non-preferred name) |
| Limaprost |
| (2E)-7-{(1R,2R,3R)-3-Hydroxy-2-[(1E,3S,5S)-3-hydroxy-5-methyl-1-nonen-1-yl]-5-oxocyclopentyl}-2-heptenoic acid |
| 9-Oxo-11a,15a-dihydroxy-17S,20-dimethylprosta-trans-2,trans-13-dienoic Acid |
| 17S,20-Dimethyl-trans-2,3-didehydro-PGE1 |
| (2E,11a,13E,15S,17S)-11,15-Dihydroxy-17,20-dimethyl-9-oxoprosta-2,13-dien-1-oic Acid |
| 17S-Methyl-w-homo-trans-D2-PGE1 |
| ONO 1206 |
| OP 1206 |